Folfiri as Third Line of Treatment

IRCCS Cancer Referral Center of Basilicata

Status: Completed

Conditions: Gastric Cancer; Ramucirumab; Third Line

Study type: Observational

Funder types: Other

Identifiers

NCT03486379

IRCCS-CROB

Details and patient eligibility

About

The aim of this study is to investigate the activity of Folfiri as Third line of treatment in mGC progressed after ramuciramb-based second line.

Enrollment: 26 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with histologically confirmed, ramucirumab pretreated metastatic gastric cancer who received
• Eastern Cooperative Oncology Group performance status ≤2 (ECOG PS)
• aged > 18 years
• neutrophil count ≥1500/μl
• platelet count ≥100 000/μl),
• renal (serum creatinine ≤1.5 mg/dl)
• liver (serum bilirubin ≤2 mg/dL) functions
• normal cardiac function,
• absence of second primary tumor other than non-melanoma skin cancer
• no concurrent uncontrolled medical illness.

Exclusion criteria

• Eastern Cooperative Oncology Group performance status >2 (ECOG PS)
• No prior treatment with ramucirumab
• operable metastatic disease were excluded from the study
• severe cardiac dysfunction, congestive heart failure or a recent myocardial infarction
• uncontrolled sites of infection.